Dextera Surgical Inc (NASDAQ:DXTR) has received a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation. Dextera Surgical’s rating score has declined by 79.6% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a 1-year consensus price objective of $0.40 for the company, according to Zacks. Zacks has also given Dextera Surgical an industry rank of 160 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised Dextera Surgical from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 10th.

A hedge fund recently raised its stake in Dextera Surgical stock. Virtu KCG Holdings LLC lifted its holdings in Dextera Surgical Inc (NASDAQ:DXTR) by 1,380.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 369,918 shares of the medical instruments supplier’s stock after buying an additional 344,933 shares during the quarter. Virtu KCG Holdings LLC owned about 4.14% of Dextera Surgical worth $111,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.49% of the company’s stock.

Dextera Surgical (DXTR) opened at $0.04 on Tuesday. The stock has a market capitalization of $2.81, a price-to-earnings ratio of -0.02 and a beta of -1.35. Dextera Surgical has a twelve month low of $0.04 and a twelve month high of $1.98.

Dextera Surgical (NASDAQ:DXTR) last issued its quarterly earnings data on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). The business had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.62 million. equities analysts anticipate that Dextera Surgical will post -0.27 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/01/23/dextera-surgical-inc-dxtr-given-0-40-consensus-target-price-by-analysts.html.

About Dextera Surgical

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Get a free copy of the Zacks research report on Dextera Surgical (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dextera Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical and related companies with MarketBeat.com's FREE daily email newsletter.